<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01920087</url>
  </required_header>
  <id_info>
    <org_study_id>AFP-001</org_study_id>
    <nct_id>NCT01920087</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain</brief_title>
  <acronym>AFP</acronym>
  <official_title>Phase II Double Blind, Randomized, Placebo Controlled, Safety and Efficacy Study of ATNC05 in Patients With Atypical Facial Pain With an Open-Label Extension Phase for Nonresponders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allodynic Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allodynic Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to test the efficacy of ATNC05 in the treatment of Atypical
      Facial Pain (AFP), also known as Persistent Idiopathic Facial Pain (PIFP). This research
      project targets patients with chronic constant facial pain and excludes patients with
      primarily paroxysmal pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ATNC05 is a rational combination of two well-characterized drugs with decades of clinical
      use. The investigators hypothesize that the combination acts synergistically to reduce AFP.

      The trial consists of a double-blind treatment period of twelve weeks with either Placebo or
      ATNC05. Subjects who do not respond to the study medication will continue on to a twelve week
      Open-Label extension phase, during which they will receive ATNC05.

      The subjects will have six office visits during the Double-Blind phase. Subjects continuing
      to the Open-Label phase will have four additional visits.

      Data gathering procedures include daily pain questionnaire forms, as well as questionnaires
      and physical examination during office visits.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change from Baseline Period Mean in Average Pain Intensity at Weeks 9-12</measure>
    <time_frame>Baseline to Weeks 9-12</time_frame>
    <description>The Brief Pain Inventory measures pain severity on an 11-point Likert Scale from 0 (no pain) to 10 (worst pain imaginable).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline Period Mean in BPI-S Measurements (Worst Pain Intensity, Least Pain Intensity, Average Pain Intensity, Right-Now Pain Intensity, and Night Pain Intensity)</measure>
    <time_frame>Baseline to Weeks 1-4, Weeks 5-8, and Weeks 9-12</time_frame>
    <description>The Brief Pain Inventory - Severity measures pain severity on an 11-point Likert Scale from 0 (no pain) to 10 (worst pain imaginable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline Period Mean in BPI-I Measurements (General Activity, Mood, Chewing Ability, Normal Work, Relationships, Sleep Quality, Enjoyment of Life, Talking, and Teeth Brushing)</measure>
    <time_frame>Baseline to Weeks 1-4, Weeks 5-8, and Weeks 9-12</time_frame>
    <description>The Brief Pain Inventory - Interference measures interference with the listed activities on an 11-point Likert Scale from 0 (does not interfere) to 10 (completely interferes)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement</measure>
    <time_frame>Weeks 1-4, Weeks 5-8, and Weeks 9-12</time_frame>
    <description>The PGI-I measures subject's assessment of how much relief the study medication provides on a scale of 0% to 100%, in increments of 10%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Analysis of CGI-S</measure>
    <time_frame>Week 1, Week 4, Week 8, Week 12</time_frame>
    <description>The Clinical Global Impression - Severity scale measures the severity of the subject's condition on a seven point scale: normal, borderline, mild, moderate, marked, severe, or extreme</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Analysis of CGI-I</measure>
    <time_frame>Week 1, Week 4, Week 8, Week 12</time_frame>
    <description>The Clinical Global Impression - Improvement scale measures the improvement of the subject's condition on a seven-point Likert scale: very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Doses of Additional Pain Medication Taken</measure>
    <time_frame>Weeks 1-4, Weeks 5-8, and Weeks 9-12</time_frame>
    <description>The amount of additional analgesic medication needed for rescue purposes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AFP Pain Disability Index</measure>
    <time_frame>Week 1, Week 4, Week 8, Week 12</time_frame>
    <description>The AFP Disability Index assesses the disability caused by AFP in various life activities. It is scored on a scale of 0-100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pittsburgh Insomnia Rating Scale 20</measure>
    <time_frame>Week 1, Week 4, Week 8, Week 12</time_frame>
    <description>The PIRS-20 assesses the difficulty the subject has had with sleeping in the previous week. It is scored on a scale of 0-60.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Atypical Facial Pain</condition>
  <condition>Persistent Idiopathic Facial Pain</condition>
  <condition>Atypical Trigeminal Neuralgia</condition>
  <condition>Neuropathic Orofacial Pain</condition>
  <condition>Neuropathic Facial Pain</condition>
  <arm_group>
    <arm_group_label>ATNC05</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once capsule twice daily for first week of treatment. Two capsules at bedtime in subsequent weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once capsule twice daily for first week of treatment. Two capsules at bedtime in subsequent weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATNC05</intervention_name>
    <description>Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.</description>
    <arm_group_label>ATNC05</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is at least 18 years but no more than 89 years of age

          -  The patient has atypical facial pain/persistent idiopathic facial pain, as diagnosed
             by the 2nd Edition of The International Headache Classification (ICHD-2), section
             13.18.4.

          -  The patient has constant pain in the face, persisting for all or most of the day (four
             or more hours per day) and present four days or more per week, with a severity of 5 or
             more (11-point scale, 0 = no pain, 10 = worst pain imaginable).

          -  The pain is chronic, present for at least six months.

          -  The patient's pain is confined at onset to a limited area on one side of the face, and
             is deep and poorly localized.

          -  The patient's pain is not associated with sensory loss or other physical signs, and
             diagnostic studies of face and jaws do not demonstrate any relevant abnormality.

          -  Patient must be willing to refrain from opioid medications during the course of the
             trial.

          -  Patients entering the study on other approved concomitant medications for pain (e.g.,
             NSAIDS, anticonvulsants, antidepressants) must continue them as a stable regimen for
             at least two weeks prior to Pre-Screening and throughout the study period.

          -  The patient must agree to limit their rescue medications to APAP (Paracetamol/
             acetaminophen).

          -  The patient must understand and be willing to cooperate with the study instructions,
             including attendance of all scheduled office visits and returning unused medication
             and vials.

          -  If the patient is a female, she must be post-menopausal, not currently pregnant or
             nursing, and using a reliable contraception method (e.g., intrauterine device (IUD),
             oral or deport contraceptive, or barrier (i.e., condom or diaphragm plus spermicide).

          -  The patient must sign an informed consent document indicating willingness to
             participate.

        Exclusion Criteria:

          -  The patient has predominantly paroxysmal facial pain consistent with the diagnosis of
             classical trigeminal neuralgia or symptomatic trigeminal neuralgia.

          -  The patient's facial pain has an identifiable cause.

          -  The patient has a positive urine drug screen during the screening visit.

          -  The patient has a history of substance abuse and/or dependency (including but not
             limited to opioid and/or alcohol dependence).

          -  The patient has been on chronic opioid therapy or has taken opioid medication â‰¤ 7 days
             prior Pre-Screening.

          -  The subject has a history of significant neurological, hepatic, renal, endocrine,
             cardiovascular, gastrointestinal, pulmonary, or metabolic disease. The subject has
             acute hepatitis or liver failure.

          -  The subject has a history of left ventricular hypertrophy, recent MI, angina,
             palpitations, dyspnea, or arrhythmia.

          -  The subject has used MAO Inhibitors within 30 days of enrollment.

          -  The patient has a history of an allergic reaction to the components in the trial
             medication.

          -  The patient is pregnant or breastfeeding.

          -  The patient has a heart rate of less than 60 beats per minute and/or systolic blood
             pressure of 90 mmHg or lower at Screening and/or medication initiation visit.

          -  The patient has another source of pain that is greater than AFP.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Annette C. Toledano MD</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2013</study_first_submitted>
  <study_first_submitted_qc>August 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2013</study_first_posted>
  <last_update_submitted>March 12, 2014</last_update_submitted>
  <last_update_submitted_qc>March 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atypical Facial Pain</keyword>
  <keyword>Persistent Idiopathic Facial Pain</keyword>
  <keyword>Atypical Trigeminal Neuralgia</keyword>
  <keyword>Orofacial Pain</keyword>
  <keyword>Orofacial neuropathic pain</keyword>
  <keyword>Fothergill Disease</keyword>
  <keyword>Tic Douloureux</keyword>
  <keyword>Prosopalgia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Facies</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Trigeminal Neuralgia</mesh_term>
    <mesh_term>Facial Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

